Insider Trading November 19, 2026 04:16 AM

MaxCyte CEO Masoud Maher Purchases $120,780 in Company Stock

Insider buy comes as MaxCyte reports strong Q3 results and Stifel reiterates Buy rating

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
MXCT

Masoud Maher, President and CEO of MaxCyte, Inc. (NASDAQ:MXCT), acquired 100,000 shares of company stock on November 17, 2026, for a total of $120,780. The purchase was executed at a weighted average price of $1.2078 per share, with individual prices ranging from $1.185 to $1.21. Following the transaction, Maher directly holds 575,000 shares. The stock currently trades at $1.25, slightly above the purchase price, and is considered undervalued with a Fair Value of $1.31. The insider buy aligns with a tip noting aggressive share buybacks by management. In other news, MaxCyte reported Q3 revenue growth of 49% to $10.2 million, surpassing estimates, with an adjusted loss per share of $0.05, better than the expected $0.0825 loss. Stifel maintained a Buy rating and $4.00 price target, citing growth momentum. Instrument demand revenue doubled year-over-year, while consumables rose 20%, marking the first year-over-year growth in eight quarters. The company also provided an expanded outlook for 2026.

MaxCyte CEO Masoud Maher Purchases $120,780 in Company Stock
MXCT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CEO Masoud Maher bought 100,000 shares for $120,780, increasing his direct holdings to 575,000 shares, signaling confidence in MaxCyte’s outlook.
  • MaxCyte’s Q3 revenue grew 49% year-over-year to $10.2 million, with adjusted loss per share narrowing to $0.05, beating estimates; Stifel maintains Buy rating and $4.00 price target.
  • The insider purchase and strong results impact the healthcare sector and the broader stock market, particularly for small-cap biotech companies.

Masoud Maher, President and Chief Executive Officer of MaxCyte, Inc. (NASDAQ:MXCT), has increased his stake in the company with the purchase of 100,000 shares of common stock, according to a regulatory filing. The transaction, dated November 17, 2026, was valued at $120,780 in aggregate.

The shares were acquired at a weighted average price of $1.2078. Individual purchase prices within the transaction ranged from $1.185 to $1.21 per share. Following this acquisition, Maher directly holds 575,000 shares of MaxCyte common stock.

MaxCyte’s stock is currently trading at $1.25, which is slightly above the CEO’s purchase price. According to analysis, the stock appears undervalued, with a Fair Value estimate of $1.31. This insider purchase aligns with a noted tip that management has been aggressively buying back shares—one of seven additional exclusive tips available to subscribers.

The purchase comes on the heels of MaxCyte’s robust third-quarter financial results, which surpassed Wall Street estimates. The company reported revenue of $10.2 million, a 49% increase compared to the same period last year. Adjusted loss per share narrowed to $0.05, better than the anticipated loss of $0.0825 per share.

Stifel reiterated its Buy rating on MaxCyte and maintained a price target of $4.00, highlighting the company’s growth momentum in the third quarter. Instrument demand revenue saw a 100% year-over-year increase, while consumables demand rose by 20%. These developments mark the first year-over-year growth MaxCyte has achieved in eight quarters. The company also shared an expanded outlook for 2026, indicating confidence in its strategic direction.

Insider transactions are closely monitored by investors as they can provide insight into management’s confidence in the company’s prospects. The CEO’s purchase may be viewed as a positive signal, particularly given the recent strong financial performance and analyst support.

Risks

  • MaxCyte’s stock is trading at $1.25, slightly above the CEO’s purchase price, and may face volatility; the healthcare sector is sensitive to reimbursement changes and clinical trial outcomes.
  • The company’s adjusted loss per share of $0.05, while improved, indicates ongoing unprofitability, posing a risk to financial stability in the competitive biotech market.
  • The expanded 2026 outlook is forward-looking and subject to execution risks, which could affect investor confidence in the healthcare and life sciences sectors.

More from Insider Trading

SmartStop Director Mueller Offloads $17,021 in Shares Near 52-Week High Nov 19, 2026 Universal Electronics Director Eric Singer Offloads $1.15 Million in Stock Across Three Sessions Nov 19, 2026 Universal Electronics Director Offloads $703,700 in Shares as Stock Surges Nov 19, 2026 RA Capital Adds to SpyGlass Pharma Stake with $32,430 Purchase Nov 19, 2026 FRP Holdings Director John D. Baker II Increases Stake with $96,349 Purchase Nov 19, 2026